Year All20242023202220212020 Mar 25, 2024 Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million PDF Version Feb 21, 2024 Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases PDF Version Nov 16, 2023 Q32 Bio and Homology Medicines Announce Merger Agreement PDF Version Nov 16, 2023 Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen PDF Version Oct 24, 2023 Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer PDF Version Sep 13, 2023 Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata PDF Version Oct 27, 2022 Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis PDF Version Sep 20, 2022 Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition PDF Version Aug 15, 2022 Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases PDF Version Jun 23, 2022 Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097 PDF Version
Mar 25, 2024 Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million PDF Version
Feb 21, 2024 Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases PDF Version
Sep 13, 2023 Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata PDF Version
Oct 27, 2022 Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis PDF Version
Sep 20, 2022 Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition PDF Version
Aug 15, 2022 Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases PDF Version
Jun 23, 2022 Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097 PDF Version